Free Trial
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • 5 stocks we like better than Denali Therapeutics.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should you invest $1,000 in Denali Therapeutics right now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover
These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.4235 of 5 stars		$21.45-0.2%N/A-7.77Moderate Buy$40.40
Ultragenyx Pharmaceutical (RARE)
4.4444 of 5 stars		$44.22+1.7%N/A-6.83Moderate Buy$88.46
Sarepta Therapeutics (SRPT)
4.8145 of 5 stars		$118.97-0.4%N/A95.18Moderate Buy$178.71
Pfizer (PFE)
4.9837 of 5 stars		$26.36+2.3%6.53%35.62Hold$32.14
Exelixis (EXEL)
4.5075 of 5 stars		$33.29-1.2%N/A21.34Moderate Buy$32.44
Moderna (MRNA)
4.2706 of 5 stars		$39.39-0.4%N/A-6.77Hold$79.50
United Therapeutics (UTHR)
4.7124 of 5 stars		$359.58-0.2%N/A15.79Moderate Buy$370.86
Biogen (BIIB)
4.6303 of 5 stars		$146.47-0.6%N/A13.23Hold$242.68
Sanofi (SNY)
3.554 of 5 stars		$47.71+0.4%3.08%24.34Buy$57.50
Eli Lilly and Company (LLY)
4.9956 of 5 stars		$767.76+1.3%0.78%83.00Moderate Buy$1,002.22
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines